CO2022017622A2 - Inhibidores de quinasa nek7 - Google Patents
Inhibidores de quinasa nek7Info
- Publication number
- CO2022017622A2 CO2022017622A2 CONC2022/0017622A CO2022017622A CO2022017622A2 CO 2022017622 A2 CO2022017622 A2 CO 2022017622A2 CO 2022017622 A CO2022017622 A CO 2022017622A CO 2022017622 A2 CO2022017622 A2 CO 2022017622A2
- Authority
- CO
- Colombia
- Prior art keywords
- nek7
- compounds
- kinase inhibitors
- activity
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022159P | 2020-05-08 | 2020-05-08 | |
| US202163170761P | 2021-04-05 | 2021-04-05 | |
| PCT/US2021/031394 WO2021242505A1 (en) | 2020-05-08 | 2021-05-07 | Inhibitors of nek7 kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022017622A2 true CO2022017622A2 (es) | 2022-12-20 |
Family
ID=77774963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0017622A CO2022017622A2 (es) | 2020-05-08 | 2022-12-06 | Inhibidores de quinasa nek7 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11161852B1 (https=) |
| EP (1) | EP4146348B1 (https=) |
| JP (2) | JP7796671B2 (https=) |
| KR (1) | KR20230008763A (https=) |
| CN (2) | CN120699028A (https=) |
| AU (1) | AU2021280893A1 (https=) |
| BR (1) | BR112022022669A2 (https=) |
| CA (1) | CA3182276A1 (https=) |
| CO (1) | CO2022017622A2 (https=) |
| DK (1) | DK4146348T3 (https=) |
| ES (1) | ES2991366T3 (https=) |
| FI (1) | FI4146348T3 (https=) |
| HR (1) | HRP20241304T1 (https=) |
| HU (1) | HUE068185T2 (https=) |
| IL (1) | IL297979A (https=) |
| LT (1) | LT4146348T (https=) |
| MX (1) | MX2022013984A (https=) |
| PH (1) | PH12022553024A1 (https=) |
| PL (1) | PL4146348T3 (https=) |
| PT (1) | PT4146348T (https=) |
| RS (1) | RS65962B1 (https=) |
| SI (1) | SI4146348T1 (https=) |
| WO (1) | WO2021242505A1 (https=) |
| ZA (1) | ZA202212146B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS65962B1 (sr) * | 2020-05-08 | 2024-10-31 | Halia Therapeutics Inc | Inhibitori nek7 kinaze |
| CN114751874B (zh) * | 2022-05-30 | 2025-01-24 | 江南大学 | 作为TRPV4-KCa2.3促耦联剂的1-苄基-4-乙基哌嗪衍生物及其应用 |
| US20250114361A1 (en) | 2022-08-29 | 2025-04-10 | Japan Tobacco Inc. | Pyrazolopyrimidine compound and pharmaceutical use thereof |
| US20240158394A1 (en) * | 2022-09-14 | 2024-05-16 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| WO2024167423A1 (en) | 2023-02-07 | 2024-08-15 | Captor Therapeutics S.A. | Gspt1 degrader compounds |
| IL324734A (en) * | 2023-05-26 | 2026-01-01 | Halia Therapeutics Inc | Polymorphs of nek 7 inhibitors |
| TW202517271A (zh) * | 2023-07-06 | 2025-05-01 | 美商哈利亞製藥公司 | Nek7激酶抑制劑之醫藥組合物 |
| WO2025067411A1 (zh) * | 2023-09-28 | 2025-04-03 | 北京普祺医药科技股份有限公司 | 一种nek7抑制剂、药物组合物及其用途 |
| WO2025140570A1 (zh) * | 2023-12-29 | 2025-07-03 | 北京普祺医药科技股份有限公司 | 一种nek7抑制剂、药物组合物及其用途 |
| WO2025160453A1 (en) * | 2024-01-25 | 2025-07-31 | Halia Therapeutics, Inc. | Heterocyclic compounds, such as ht-6184, for use in the treatment of pain |
| WO2025190317A1 (en) * | 2024-03-13 | 2025-09-18 | National Institute Of Biological Sciences, Beijing | Urea compounds as nlrp3 agonists |
| CN118812538A (zh) * | 2024-06-18 | 2024-10-22 | 南京健康产业研究院 | 一种具有抗肾癌活性的化合物及其制备方法与应用 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| AU2000240570A1 (en) | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
| AU9598601A (en) | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| TWI263640B (en) | 2001-12-19 | 2006-10-11 | Bristol Myers Squibb Co | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| GB0225579D0 (en) | 2002-11-02 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
| EP1684762A4 (en) | 2003-11-13 | 2009-06-17 | Ambit Biosciences Corp | UREA DERIVATIVES AS MODULATORS OF KINASE |
| MX2007011041A (es) | 2005-03-10 | 2008-02-22 | Cgi Pharmaceuticals Inc | Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas. |
| US20100249030A1 (en) | 2007-07-31 | 2010-09-30 | Schering Corporation | Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment |
| EP3147281A1 (en) | 2008-03-17 | 2017-03-29 | Ambit Biosciences Corporation | Quinazoline derivatives as raf kinase modulators and methods of use thereof |
| CA2737639A1 (en) | 2008-09-25 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the cb2 receptor |
| TW201018682A (en) | 2008-09-25 | 2010-05-16 | Kyorin Seiyaku Kk | Heterocyclic biaryl derivative, and pde inhibitor comprising same as active ingredient |
| MX2012001974A (es) | 2009-08-19 | 2012-04-11 | Ambit Biosciences Corp | Compuestos de biarilo y metodos de uso de los mismos. |
| JP2013525308A (ja) | 2010-04-16 | 2013-06-20 | キュリス，インコーポレイテッド | Ｋ−ｒａｓ変異を有する癌の治療 |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| EP2802212B1 (en) | 2012-01-12 | 2015-12-30 | Basf Se | Herbicidal isoxazolo[5,4-b]pyridines |
| EP2997030B1 (en) | 2013-05-14 | 2017-08-09 | Nerviano Medical Sciences S.R.L. | Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors |
| CA2914815A1 (en) | 2013-06-11 | 2014-12-18 | Kala Pharmaceuticals, Inc. | Urea derivatives and uses thereof |
| EA029412B1 (ru) | 2013-06-28 | 2018-03-30 | Бейджин, Лтд. | Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf |
| US9290519B2 (en) | 2013-11-15 | 2016-03-22 | Exxonmobil Chemical Patents Inc. | Pyridyldiamido transition metal complexes, production and use thereof |
| KR102562866B1 (ko) | 2014-11-14 | 2023-08-04 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 단백질 키나아제 억제제로서의 6-아미노-7-바이사이클로-7-데아자-퓨린 유도체 |
| US10688077B2 (en) | 2015-02-26 | 2020-06-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inflammasome activation in myelodysplastic syndromes |
| US10259816B2 (en) | 2015-04-24 | 2019-04-16 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof |
| RU2724345C2 (ru) | 2015-10-09 | 2020-06-23 | Галапагос Нв | N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ |
| JP6910359B2 (ja) | 2016-01-22 | 2021-07-28 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体 |
| CN107176951A (zh) | 2016-03-11 | 2017-09-19 | 恩瑞生物医药科技（上海）有限公司 | 一种脲类化合物、其制备方法及其医药用途 |
| US10167703B2 (en) | 2016-03-31 | 2019-01-01 | Saudi Arabian Oil Company | Optimal well placement under constraints |
| JP6867417B2 (ja) | 2016-06-21 | 2021-04-28 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤としてのｎ−（置換フェニル）−スルホンアミド誘導体 |
| US20190241573A1 (en) | 2016-07-20 | 2019-08-08 | Glaxosmithkline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
| EP3296297A1 (en) | 2016-09-15 | 2018-03-21 | Centre National De La Recherche Scientifique | Benzimidazol derivatives for treating filovirus infection |
| AU2018272986A1 (en) | 2017-05-26 | 2019-12-12 | Ichnos Sciences SA | Novel inhibitors of MAP4K1 |
| EP3638669A1 (en) | 2017-06-13 | 2020-04-22 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| WO2018228925A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| KR20200087759A (ko) | 2017-11-09 | 2020-07-21 | 인플라좀 리미티드 | 신규한 설폰아마이드 카복스아마이드 화합물 |
| CA3093469A1 (en) | 2018-03-09 | 2019-09-12 | The Brigham And Women's Hospital, Inc. | Combination therapy for cardiovascular diseases |
| IL277408B2 (en) | 2018-04-05 | 2024-08-01 | Merck Patent Gmbh | Heteroaryl compounds as IRAK type II inhibitors and their use |
| CN112654350A (zh) | 2018-07-03 | 2021-04-13 | 诺华股份有限公司 | 使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法 |
| WO2020035495A1 (en) | 2018-08-14 | 2020-02-20 | Cynora Gmbh | Organic molecules for optoelectronic devices |
| JP2021536458A (ja) | 2018-09-04 | 2021-12-27 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | アリール炭化水素レセプター・アンタゴニスト及び使用方法 |
| GB201815045D0 (en) | 2018-09-14 | 2018-10-31 | Univ Ulster | Bispecific antibody targeting IL-1R1 and NLPR3 |
| CN113271940A (zh) | 2018-10-15 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| CN113226309B (zh) | 2018-12-03 | 2024-10-29 | 珠海岐微生物科技有限公司 | 一种治疗年龄相关性黄斑变性的方法 |
| WO2020139748A1 (en) | 2018-12-28 | 2020-07-02 | Cedars-Sinai Medical Center | Methods of treating inflammatory bowel diseases that target ripk2 |
| EP3908274A1 (en) | 2019-01-11 | 2021-11-17 | Universitätsspital Basel | Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery |
| EP3917907B1 (en) | 2019-01-29 | 2025-05-21 | Universitá Degli Studi Di Salerno | Modulators of potassium ion channels and uses thereof |
| CN111646995B (zh) | 2019-03-04 | 2023-03-21 | 四川大学 | 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途 |
| GB201905265D0 (en) | 2019-04-12 | 2019-05-29 | Inflazome Ltd | Inflammasome inhibition |
| US11559536B2 (en) | 2019-05-20 | 2023-01-24 | Duke University | Compositions and methods for the treatment of inflammation in urological pathology |
| CA3152508A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting pyrrolopyrimidine compounds |
| WO2021057877A1 (zh) * | 2019-09-26 | 2021-04-01 | 深圳市塔吉瑞生物医药有限公司 | 取代的芳香稠合环衍生物及其组合物及用途 |
| US20230140941A1 (en) | 2020-03-13 | 2023-05-11 | University Of Maryland, Baltimore | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors |
| AU2020436612A1 (en) | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
| US20230172941A1 (en) | 2020-03-20 | 2023-06-08 | The Johns Hopkins University | Prophylaxis and treatment of pathogenic coronavirus infections |
| RS65962B1 (sr) * | 2020-05-08 | 2024-10-31 | Halia Therapeutics Inc | Inhibitori nek7 kinaze |
| WO2021226547A2 (en) | 2020-05-08 | 2021-11-11 | Halia Therapeutics, Inc. | Targeted nek7 inhibition for modulation of the nlrp3 inflammasome |
| US20230257367A1 (en) | 2020-06-02 | 2023-08-17 | Chengdu Kanghong Pharmaceutical Co., Ltd. | Novel thyroid hormone beta receptor agonist |
| EP4161933A1 (en) | 2020-06-08 | 2023-04-12 | Halia Therapeutics, Inc. | Inhibitors of nek7 kinase |
| GB202010464D0 (en) | 2020-07-08 | 2020-08-19 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| EP4232020A4 (en) | 2020-10-21 | 2024-08-07 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
| US20240400551A1 (en) | 2021-01-25 | 2024-12-05 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| WO2022192944A1 (en) | 2021-03-15 | 2022-09-22 | Genieus Genomics Pty Ltd | Combination therapy for treatment of als |
| WO2022216680A1 (en) | 2021-04-05 | 2022-10-13 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| WO2022226349A1 (en) | 2021-04-22 | 2022-10-27 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| US20240336563A1 (en) | 2021-04-26 | 2024-10-10 | The Regents Of The University Of California | G-alpha-s inhibitors and uses thereof |
| US20240287081A1 (en) | 2021-06-09 | 2024-08-29 | Icahn School Of Medicine At Mount Sinai | Perfluoroalkane substituted pyrazolo[3,4-d]pyrimidin and pyrrolo[2,3-d]pyrimidin compounds and uses thereof |
| CN115616216B (zh) | 2021-07-15 | 2025-08-12 | 华南理工大学 | 抑制或阻断faah与nlrp3之间相互作用的制剂的用途 |
| IL309085A (en) | 2021-07-23 | 2024-02-01 | Novartis Ag | Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis |
| TW202333693A (zh) | 2021-12-31 | 2023-09-01 | 大陸商上海翰森生物醫藥科技有限公司 | 苯并哌啶衍生物調節劑、其製備方法和應用 |
-
2021
- 2021-05-07 RS RS20241030A patent/RS65962B1/sr unknown
- 2021-05-07 CN CN202510888448.XA patent/CN120699028A/zh active Pending
- 2021-05-07 KR KR1020227041803A patent/KR20230008763A/ko active Pending
- 2021-05-07 IL IL297979A patent/IL297979A/en unknown
- 2021-05-07 WO PCT/US2021/031394 patent/WO2021242505A1/en not_active Ceased
- 2021-05-07 PL PL21770328.9T patent/PL4146348T3/pl unknown
- 2021-05-07 SI SI202130195T patent/SI4146348T1/sl unknown
- 2021-05-07 ES ES21770328T patent/ES2991366T3/es active Active
- 2021-05-07 BR BR112022022669A patent/BR112022022669A2/pt unknown
- 2021-05-07 PT PT217703289T patent/PT4146348T/pt unknown
- 2021-05-07 DK DK21770328.9T patent/DK4146348T3/da active
- 2021-05-07 AU AU2021280893A patent/AU2021280893A1/en active Pending
- 2021-05-07 EP EP21770328.9A patent/EP4146348B1/en active Active
- 2021-05-07 CA CA3182276A patent/CA3182276A1/en active Pending
- 2021-05-07 LT LTEPPCT/US2021/031394T patent/LT4146348T/lt unknown
- 2021-05-07 HU HUE21770328A patent/HUE068185T2/hu unknown
- 2021-05-07 US US17/315,209 patent/US11161852B1/en active Active
- 2021-05-07 CN CN202180048858.3A patent/CN115843272B/zh active Active
- 2021-05-07 PH PH1/2022/553024A patent/PH12022553024A1/en unknown
- 2021-05-07 FI FIEP21770328.9T patent/FI4146348T3/fi active
- 2021-05-07 MX MX2022013984A patent/MX2022013984A/es unknown
- 2021-05-07 HR HRP20241304TT patent/HRP20241304T1/hr unknown
- 2021-05-07 JP JP2022567839A patent/JP7796671B2/ja active Active
- 2021-09-14 US US17/475,220 patent/US11713321B2/en active Active
-
2022
- 2022-11-07 ZA ZA2022/12146A patent/ZA202212146B/en unknown
- 2022-12-06 CO CONC2022/0017622A patent/CO2022017622A2/es unknown
-
2023
- 2023-05-23 US US18/322,380 patent/US12091413B2/en active Active
-
2025
- 2025-12-23 JP JP2025278930A patent/JP2026067870A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022017622A2 (es) | Inhibidores de quinasa nek7 | |
| CO2023014204A2 (es) | Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7) | |
| CO2022019131A2 (es) | Inhibidores de la quinasa nek7 | |
| DOP2022000124A (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
| MX2021008358A (es) | Lipidos para la administracion de agentes activos en nanoparticulas lipidicas. | |
| MX2018000777A (es) | Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c. | |
| CO2024015820A2 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| CO2024015816A2 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| UY29087A1 (es) | Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico | |
| MX2016004360A (es) | Inhibidores de kras g12c. | |
| CO2023013050A2 (es) | Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| UY39625A (es) | Derivados tricíclicos útiles como inhibidores de parp7 | |
| CO2021010493A2 (es) | Compuestos de halo-alilamina y uso de los mismos | |
| ECSP19026973A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| CL2023003036A1 (es) | Inhibidores heteroaromáticos bicíclicos de la klk5 | |
| MX2024010321A (es) | Inhibidores de la quinasa tipo polo 4 (plk4), composiciones farmaceuticas, metodos de preparacion y usos de los mismos | |
| UY28979A1 (es) | Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3 | |
| UY38006A (es) | Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones | |
| CO2026000093A2 (es) | Composiciones farmacéuticas para inhibidores de la cinasa nek7 | |
| CO2023012903A2 (es) | Derivados de pirimidina útiles como inhibidores de la proteína cinasa de repetición 2 rica en leucina (lrrk2) | |
| MX2022005199A (es) | Inhibidores de ssao y uso de los mismos. | |
| ECSP088237A (es) | Derivados de quinolina y uso como agentes antitumor | |
| AR134428A1 (es) | Inhibidores de jak2 v617f y métodos de uso de los mismos |